Sepsis News and Research

Latest Sepsis News and Research

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

MIT researchers devise new system to genetically engineer viruses to combat harmful bacteria

MIT researchers devise new system to genetically engineer viruses to combat harmful bacteria

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Tackling MRSA with bacteriophage

Tackling MRSA with bacteriophage

Liver failure patients may benefit from CSF-1 treatment that aids the immune system to combat infections

Liver failure patients may benefit from CSF-1 treatment that aids the immune system to combat infections

Report highlights remarkable decline in child mortality, but MDG target still missed by wide margin

Report highlights remarkable decline in child mortality, but MDG target still missed by wide margin

Survival and health outcomes for extremely preterm infants improve over 20 years

Survival and health outcomes for extremely preterm infants improve over 20 years

Potential new treatment for sepsis and ARDS

Potential new treatment for sepsis and ARDS

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Brain scans may help predict patients' response to antipsychotic drug treatment

Brain scans may help predict patients' response to antipsychotic drug treatment

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Researchers report new breakthrough in countering deadly effects of radiation exposure

Researchers report new breakthrough in countering deadly effects of radiation exposure

Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Pitt unveils research-based guidance to improve compliance while treating sepsis

Pitt unveils research-based guidance to improve compliance while treating sepsis

Early exposure to inflammatory cytokines can paralyze CD4 T cells

Early exposure to inflammatory cytokines can paralyze CD4 T cells

U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

Researchers describe new Lab-on-a-Disc device for fast and reliable diagnostics of urinary tract infections

Researchers describe new Lab-on-a-Disc device for fast and reliable diagnostics of urinary tract infections

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.